Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 71,50
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 72 pages. 8.66x5.91x0.17 inches. In Stock.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Osteosarcoma | Investigation of potential new treatments for the bone cancer Osterosarcoma | Thanuri Jeevananda | Taschenbuch | 72 S. | Englisch | 2019 | LAP LAMBERT Academic Publishing | EAN 9786139947591 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing Aug 2019, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in anti-tumour activity by exerting DNA damage. This study investigated the efficacy and safety of a chosen panel of chemotherapy drugs on murine osteosarcoma (OS) cell lines. 72 pp. Englisch.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: moluna, Greven, Deutschland
EUR 34,25
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Jeevananda ThanuriThanuri Jeevananda is a Microbiologist, a researcher who has received B.Sc. in Microbiology and M.Sc. in Biotechnology. Her educational background in science and technology has always mesmerised her to investigate t.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing Aug 2019, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in anti-tumour activity by exerting DNA damage. This study investigated the efficacy and safety of a chosen panel of chemotherapy drugs on murine osteosarcoma (OS) cell lines.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 72 pp. Englisch.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2019
ISBN 10: 6139947596 ISBN 13: 9786139947591
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in anti-tumour activity by exerting DNA damage. This study investigated the efficacy and safety of a chosen panel of chemotherapy drugs on murine osteosarcoma (OS) cell lines.